CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
Study Details
Study Description
Brief Summary
T-cell lymphoma/leukemia is a group of highly lethal diseases with a high relapse rate and poor prognosis. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.
In this study we aim to test the safety and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
T-cell lymphoma accounts for 10%~15% of non-Hodgkin lymphoma in China. According to the World Health Organization (WHO), T-cell lymphoma was divided into the following subtypes: T-cell, NK cell lymphoma/leukemia. There were two major categories: anterior T-cell tumors and posterior thymic T-cell lymphomas, which originate from lymph nodes, extranodal tissue, or skin; mature or peripheral T-cell lymphomas.
Generally speaking, the relapse accounts for 50-60% after first-line treatment, while the remission rate with second-line treatment was extremely low. Collectively, there was an urgent need for new treatment modalities to improve the clinical outcomes of these patients.
CD7 is a transmembrane glycoprotein that plays an important role in T-cell and T-cell/B-cell interactions during early lymphoid development. The expression of CD7 persist from stem to mature T cells. CD7 was proved to be widely expressed in T-cell malignant, which makes it a promising therapeutic target.
In this study we aim to testify the safy and efficacy of CD7 CAR-T cells in T-cell lymphoma/leukemia.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment group CD7 CAR-T treatment group |
Biological: CD7 CAR-T cells
patient was subjected to 0.5-2×10^6 cells/kg of CD7 CAR- T
|
Outcome Measures
Primary Outcome Measures
- TEAEs [From date of initial treatment to the 30 days after treatment]
Adverse events during treatment
Secondary Outcome Measures
- overall response rate [baseline and 8 weeks, up to 1 year]
the proportion of complete and partial response patients
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 18-75 (≥ 18 years old, ≤ 75 years old), gender is not limited;
-
The subject voluntarily participates in the research and signs the "Informed Consent" by himself or his legal guardian;
-
According to the National Comprehensive Cancer Network (NCCN) T lymphocytic lymphoma (2020.V1)/acute lymphoblastic leukemia (2020. V1) practice guidelines, diagnosed with T-cell lymphoma;
-
Meet the diagnostic criteria for relapsed/refractory T-cell lymphoma, including any of the following:
- Failure to obtain CR at the end of induction therapy; 2) Patients who have obtained CR have blasts in peripheral blood or bone marrow (proportion >5%), or extramedullary diseases; 5. Have not received antibody therapy within 2 weeks before cell therapy; 6. ECOG score of 0-2; 7. The subject has no contraindications to peripheral apheresis; 8. Expected survival time of more than 3 months.
Exclusion Criteria:
-
Those who have a history of allergy to any of the ingredients in cell products;
-
Laboratory tests for the following: including but not limited to, total serum bilirubin≧ 1.5mg/dl; Serum ALT or AST greater than 2.5 times the upper limit of normal; Blood creatinine≧ 2.0mg/dl; Platelet count≦ 10×109/L;
-
Patients with cardiac insufficiency who belong to class III or IV according to the New York Cardiology Association (NYHA) cardiac function grading standards; or echocardiography with left ventricular ejection fraction (LVEF) < 50%;
-
Abnormal lung function, blood oxygen saturation under indoor air < 92%;
-
Myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other serious clinical heart disease within 12 months before enrollment;
-
Grade 3 hypertension with poor control of blood pressure with medication;
-
Patients with other advanced tumors (those who are assessed as stable after treatment of other tumors can be enrolled);
-
Previous head trauma, impaired consciousness, epilepsy, more serious cerebral ischemia or cerebral hemorrhage disease;
-
Known central nervous system leukemia (CNS2 or CNS3), resistance to intrathecal chemotherapy injections and/or ongoing head and/or spinal radiation therapy; Previous CNS history but has been effectively controlled to allow enrollment;
-
Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressant therapy;
-
presence of uncontrolled, active infection;
-
Have previously used any CAR-T cell product or other genetically modified T cell therapy;
-
Live vaccination within 4 weeks prior to enrollment;
-
HIV, HBV, HCV and TPPA/RPR infections, and HBV carriers;
-
Subject has a history of alcoholism, drug addiction or mental illness;
-
The subject has participated in any other clinical research within 3 months before joining this clinical study;
-
Female subjects have any of the following conditions: a) are pregnant/lactating; or b) have plans to become pregnant during the trial; or c) are of childbearing potential and unable to use effective contraception;
-
There are other circumstances in which the investigator believes that the subject is not suitable for this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Li Yu | Shenzhen | Guangdong | China | 518000 |
Sponsors and Collaborators
- Shenzhen University General Hospital
Investigators
- Principal Investigator: Li Yu, Dr, Shenzhen University General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HEM-ONCO-017